Association of factor expression levels with annual bleeding rate in people with haemophilia B

Introduction Gene therapy clinical trials measure steady‐state clotting factor expression levels (FELs) to evaluate the modulation of the bleeding phenotype, aiming to offer consistent protection against breakthrough bleeding events. The link between FELs and bleeding risk in people with haemophilia...

Ausführliche Beschreibung